EPS for Halozyme Therapeutics, Inc. (HALO) Expected At $-0.23

October 13, 2018 - By Adrian Mccoy

Halozyme Therapeutics, Inc. (NASDAQ:HALO) LogoInvestors sentiment decreased to 0.95 in 2018 Q2. Its down 0.56, from 1.51 in 2018Q1. It is negative, as 25 investors sold Halozyme Therapeutics, Inc. shares while 59 reduced holdings. 25 funds opened positions while 55 raised stakes. 118.72 million shares or 0.69% less from 119.54 million shares in 2018Q1 were reported.
Schwab Charles Investment Mgmt Inc accumulated 999,260 shares. Savings Bank Of America Corporation De holds 0% or 167,497 shares in its portfolio. Hightower Limited Liability Corporation accumulated 21,349 shares. Zurcher Kantonalbank (Zurich Cantonalbank) owns 7,361 shares or 0% of their US portfolio. First Light Asset Mgmt Limited Liability Company holds 889,729 shares. Savings Bank Of New York Mellon Corp holds 0.01% or 1.71M shares. Principal Grp Inc has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Citadel Advsr Limited holds 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 124,745 shares. Granite Invest Prtnrs Ltd Liability Co holds 0.78% or 734,528 shares. Los Angeles Capital Mgmt And Equity Rech has 76,714 shares for 0.01% of their portfolio. Blackrock reported 0.01% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Suntrust Banks holds 0% or 20,210 shares. Voya Management Llc has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). 21,680 were accumulated by Horizon Kinetics Limited Liability Corp. California Public Employees Retirement System invested in 189,002 shares.

Analysts expect Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report $-0.23 EPS on November, 6.They anticipate $0.25 EPS change or 1,250.00 % from last quarter’s $0.02 EPS. After having $-0.16 EPS previously, Halozyme Therapeutics, Inc.’s analysts see 43.75 % EPS growth. The stock increased 1.73% or $0.29 during the last trading session, reaching $17.1. About 759,544 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 32.24% since October 14, 2017 and is uptrending. It has outperformed by 16.62% the S&P500.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

Among 4 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Halozyme Therapeutics had 4 analyst reports since May 11, 2018 according to SRatingsIntel. On Friday, May 11 the stock rating was downgraded by Barclays Capital to “Underweight”. The company was maintained on Monday, May 14 by Canaccord Genuity. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Market Perform” rating given on Wednesday, August 8 by BMO Capital Markets.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company has market cap of $2.45 billion. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. It has a 32.7 P/E ratio. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Another recent and important Halozyme Therapeutics, Inc. (NASDAQ:HALO) news was published by Benzinga.com which published an article titled: “26 Stocks Moving In Tuesday’s Pre-Market Session” on October 09, 2018.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>